US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

39.37

-0.0843-0.21%

Volume:6K

Turnover:250.29K

Market Cap:7.87M

PE:- -

High:39.87

Open:39.87

Low:39.22

Close:39.46

52wk High:43.01

52wk Low:25.42

Shares:200.00K

Float Shares:200.00K

Volume Ratio:1.82

T/O Rate:3.17%

Dividend:0.32

Dividend Rate:0.81%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Brain-Computer Interfaces Expand Horizons: MRI Technology Enters the Equation

Beijing-Tianjin-Hebei Region Collaborates on Brain-Computer Interface Quality Chain, Outlining Five Key Focus Areas

Brain-Computer Interface Standards Blueprint Unveiled: CITIC Securities Highlights Three Key Investment Directions

Mayor Zhang Ke Chairs Meeting to Accelerate Brain-Computer Interface Industry Development

China's MIIT Seeks Feedback on Brain-Computer Interface Standards, Opening New Avenues for Consumer-Grade Devices

MIIT Targets 40+ Brain-Computer Interface Standards by 2028, Aiming for 100+ Enterprise Adoption

Public Feedback Sought on Draft Plan to Establish 40+ Brain-Computer Interface Standards by 2028

Ministry Seeks Public Input on Draft Standards for Humanoid Robotics and Brain-Computer Interface Industries

Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study

The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1

THOMSON REUTERS

From Tailored Policies to Universal Coverage: The Long Road Ahead for Brain-Computer Interface Insurance

Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?

Simply Wall St.

Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says

MT Newswires Live

Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating

MT Newswires Live

Scholar Rock price target raised to $64 from $58 at Wedbush

Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch upon FDA Approval by Sept 30, 2026 Pdufa Date

THOMSON REUTERS

Scholar Rock Holding Corporation - Withdraws Apitegromab Maa in Europe; to Resubmit with Alternate Fill-Finish Facility

THOMSON REUTERS

Scholar Rock Holding Corporation - Pmda Agrees no Additional Clinical Studies Required; Scholar Rock to Submit Apitegromab Jnda by Ye 2026

THOMSON REUTERS

Scholar Rock Withdraws EU Apitegromab Filing After FDA Flags Catalent Indiana Plant with OAI Inspection Rating

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/IBRN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":39.3744,"timestamp":1788465600000,"preClose":39.4587,"halted":0,"volume":6342,"delay":0,"changeRate":-0.0021364109816085913,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.0843,"latestTime":"09-04 07:32:36 EDT","open":39.87,"high":39.87,"low":39.22,"amount":250291,"amplitude":0.016473,"askPrice":62.6,"askSize":100,"bidPrice":37.05,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788528600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":39.3744,"sharesOutstanding":150000,"nav":39.408165,"aum":7881633,"dividendRate":0.008114,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.38,"preClose":39.3744,"latestTime":"16:10 EDT","volume":6,"amount":235.9776,"timestamp":1788466204933,"change":0.0056,"changeRate":0.000142,"amplitude":0},"volumeRatio":1.8220997165186916,"impliedVol":0.0707,"impliedVolPercentile":0.247},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.8220997165186916,"shares":200000,"dividePrice":0.3195,"high":39.87,"amplitude":0.016473,"preClose":39.4587,"low":39.22,"week52Low":25.4196,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":39.3744,"committee":-0.980198,"eps":0,"divideRate":0.008114,"volume":6342,"delay":0,"ttmEps":0,"open":39.87,"prevYearClose":32.3193,"prevWeekClose":39.2301,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":40.2953,"twentyDayClose":38.5746,"sixtyDayClose":34.7298},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1136916155","title":"Brain-Computer Interfaces Expand Horizons: MRI Technology Enters the Equation","url":"https://stock-news.laohu8.com/highlight/detail?id=1136916155","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136916155?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:41","pubTimestamp":1787758900,"startTime":"0","endTime":"0","summary":"The brain-computer interface (BCI) sector is now shifting its focus towards building out the necessary supporting infrastructure.On August 25th, the Department of Science and Technology of the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140498789","title":"Beijing-Tianjin-Hebei Region Collaborates on Brain-Computer Interface Quality Chain, Outlining Five Key Focus Areas","url":"https://stock-news.laohu8.com/highlight/detail?id=1140498789","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140498789?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:21","pubTimestamp":1787746885,"startTime":"0","endTime":"0","summary":"The market regulatory authorities of Beijing, Tianjin, and Hebei have jointly released a new work plan aimed at strengthening the quality chain for the brain-computer interface (BCI) industry across...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186574991","title":"Brain-Computer Interface Standards Blueprint Unveiled: CITIC Securities Highlights Three Key Investment Directions","url":"https://stock-news.laohu8.com/highlight/detail?id=1186574991","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186574991?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:28","pubTimestamp":1787704129,"startTime":"0","endTime":"0","summary":"According to a research report released by CITIC Securities, the newly issued \"National Brain-Computer Interface Industry Standards System Construction Guide (2026 Edition)\" establishes a...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1255011170.USD","06030","LU2580892789.USD","BK0183","LU1794554557.SGD","LU2289578879.USD","LU2580892862.HKD","LU0405327148.USD","600030","BK1564","BK0028","LU0405327494.USD","LU1997245177.USD","LU1328615791.USD","BK1516","BK1521","LU1997245094.SGD","BK0012","LU2148510915.USD","BK0188","BK0196","LU1655091616.SGD","LU1720050803.USD","BK0276","BK1147","LU2495084118.USD","MNTL","LU1064131003.USD","LU1064130708.USD","LU1781817850.SGD","LU1997244956.HKD","LU1580142542.USD","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163741798","title":"Mayor Zhang Ke Chairs Meeting to Accelerate Brain-Computer Interface Industry Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1163741798","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163741798?lang=en_us&edition=fundamental","pubTime":"2026-08-26 08:11","pubTimestamp":1787703065,"startTime":"0","endTime":"0","summary":"On August 25, Mayor Zhang Ke chaired a special meeting to review the progress of the brain-computer interface (BCI) industry's development. During the session, he responded on-site to the development...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179760819","title":"China's MIIT Seeks Feedback on Brain-Computer Interface Standards, Opening New Avenues for Consumer-Grade Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1179760819","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179760819?lang=en_us&edition=fundamental","pubTime":"2026-08-25 21:51","pubTimestamp":1787665880,"startTime":"0","endTime":"0","summary":"China's Ministry of Industry and Information Technology (MIIT) has released a draft proposal for a national brain-computer interface (BCI) industry standards framework, setting ambitious targets for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155002749","title":"MIIT Targets 40+ Brain-Computer Interface Standards by 2028, Aiming for 100+ Enterprise Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=1155002749","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155002749?lang=en_us&edition=fundamental","pubTime":"2026-08-25 11:02","pubTimestamp":1787626972,"startTime":"0","endTime":"0","summary":"The Ministry of Industry and Information Technology (MIIT) has unveiled a draft blueprint for a national standards framework in the brain-computer interface (BCI) sector, signaling a major push to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172802650","title":"Public Feedback Sought on Draft Plan to Establish 40+ Brain-Computer Interface Standards by 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=1172802650","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172802650?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:41","pubTimestamp":1787625698,"startTime":"0","endTime":"0","summary":"The Ministry of Industry and Information Technology's Science and Technology Division released the draft National Brain-Computer Interface Industry Standards System Construction Guidelines (2026...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177339202","title":"Ministry Seeks Public Input on Draft Standards for Humanoid Robotics and Brain-Computer Interface Industries","url":"https://stock-news.laohu8.com/highlight/detail?id=1177339202","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177339202?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:40","pubTimestamp":1787622028,"startTime":"0","endTime":"0","summary":"The Ministry of Industry and Information Technology (MIIT) has initiated a public consultation on a draft framework for standardizing the humanoid robotics industry, as announced on the evening of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UBOT","PBOT","IBRN","ROBT","RTOO","IQM","WDRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662620199","title":"Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620199?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610625,"startTime":"0","endTime":"0","summary":"Alkermes’ alixorexton posts positive Phase 2 Vibrance-1 results in narcolepsy type 1 studyAlkermes reported publication of positive Phase 2 Vibrance-1 results for alixorexton in adults with narcolepsy type 1 in The Lancet Neurology.Results were previously announced, not newly presented, showing improved daytime wakefulness and sleepiness measures versus placebo.Study also indicated reduced cataplexy at one dose, with broader patient-reported benefits in daily functioning.Safety profile appeared generally well tolerated, with mostly mild-to-moderate adverse events and no serious treatment-emergent events reported.Positive Phase 2 readouts supported the launch of the global Phase 3 Brilliance program testing once-daily and split-dose regimens in narcolepsy types 1 and 2.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL56tjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","PSCH","IBRN","ALKS","MEDX","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201993","title":"The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201993?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7VQ936:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","ALKS","PSCH","BK4139","MEDX","FBT","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135099508","title":"From Tailored Policies to Universal Coverage: The Long Road Ahead for Brain-Computer Interface Insurance","url":"https://stock-news.laohu8.com/highlight/detail?id=1135099508","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135099508?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:31","pubTimestamp":1787574680,"startTime":"0","endTime":"0","summary":"The first-of-its-kind invasive brain-computer interface (BCI) surgery accident insurance policy has officially filled a critical gap in China's clinical translation risk protection, yet the journey...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222175","title":"Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222175","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661222175?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:20","pubTimestamp":1787559646,"startTime":"0","endTime":"0","summary":"Earlier this week, Scholar Rock announced it had removed Catalent Indiana from all commercial fill-finish roles in apitegromab’s U.S. BLA for spinal muscular atrophy, withdrawn and planned to resubmit its European filing with an alternate facility, and secured PMDA alignment to file a Japanese application without new local trials.\nThis set of regulatory and manufacturing moves materially reduces operational risk around apitegromab’s global rollout by shifting to a compliant U.S. facility...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/scholar-rock-srrk-is-up-85-after-de-risking-apitegromabs-glo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/scholar-rock-srrk-is-up-85-after-de-risking-apitegromabs-glo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IBRN","SRRK","AIPO","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661292181","title":"Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2661292181","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661292181?lang=en_us&edition=fundamental","pubTime":"2026-08-22 03:03","pubTimestamp":1787339001,"startTime":"0","endTime":"0","summary":"Scholar Rock's  latest update further de-risks the global apitegromab regulatory path, given the potential approval in the US and clear view on the Japan registration path, offsetting a delay in Europe, Wedbush said Friday.Earlier, Scholar Rock confirmed removal of Novo Nordisk's  Catalent Indiana as a commercial fill-finish facility from its US biologics license application, and it expects an approval decision from the US Food and Drug Administration by Sept. 30 for apitegromab as a treatment for spinal muscular atrophy.In Europe, Scholar Rock said it withdrew its marketing authorization application following the Catalent inspection issue and plans to resubmit with the new facility. In Japan, no additional clinical studies are needed, allowing a new drug application filing by year-end.Wedbush reiterated its outperform rating on Scholar Rock's stock and raised its price target to $64 from $58.Price: 56.16, Change: +0.91, Percent Change: +1.64","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["THNR","SRRK","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294877","title":"Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661294877?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:45","pubTimestamp":1787330734,"startTime":"0","endTime":"0","summary":"Price: 56.19, Change: +0.94, Percent Change: +1.70","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SRRK","THNR","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661729187","title":"Scholar Rock price target raised to $64 from $58 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2661729187","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661729187?lang=en_us&edition=fundamental","pubTime":"2026-08-21 23:40","pubTimestamp":1787326815,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Scholar Rock (SRRK) to $64 from $58 and keeps an Outperform rating on the shares. Published first on TheF...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-64-from-58-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-64-from-58-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","BK4139","THNR","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661442293","title":"Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661442293","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661442293?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:10","pubTimestamp":1787317815,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced it has removed Catalent Indiana (NVO) as a commercial fill-finish facility from its apitegromab Biologics License App...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-removes-catalent-indiana-from-apitegromab-bla-under-fda-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-removes-catalent-indiana-from-apitegromab-bla-under-fda-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","THNR","BK4139","BK4007","BK4530","SRRK","BK4585","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661829358","title":"Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch upon FDA Approval by Sept 30, 2026 Pdufa Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2661829358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661829358?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:07","pubTimestamp":1787317634,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","THNR","BK4139","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661293583","title":"Scholar Rock Holding Corporation - Withdraws Apitegromab Maa in Europe; to Resubmit with Alternate Fill-Finish Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2661293583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661293583?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:07","pubTimestamp":1787317634,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0ID:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","THNR","IBRN","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661129353","title":"Scholar Rock Holding Corporation - Pmda Agrees no Additional Clinical Studies Required; Scholar Rock to Submit Apitegromab Jnda by Ye 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661129353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661129353?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:07","pubTimestamp":1787317634,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0ID:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661300293","title":"Scholar Rock Withdraws EU Apitegromab Filing After FDA Flags Catalent Indiana Plant with OAI Inspection Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2661300293","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661300293?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:06","pubTimestamp":1787317583,"startTime":"0","endTime":"0","summary":"Scholar Rock withdraws EU apitegromab filing after FDA flags Catalent Indiana plant with OAI inspection ratingScholar Rock removed Catalent Indiana as an apitegromab fill-finish site from its FDA BLA ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL5lyPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","BK4139","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}